This week, low-dose azithromycin did not improve cough in patients with IPF; tele-pulmonary rehab may lower barriers to care; the J&J vaccine provides 8-month protection from the delta variant; a daily ECMO liberation protocol was found to be safe and feasible; and portable air cleaners could reduce exposure to SARS-CoV-2 aerosols.

Read the full coverage here:

Study does not support low-dose azithromycin to treat chronic cough in IPF

Telehealth pulmonary rehabilitation program for COPD accessible, feasible, safe

J&J vaccine protects against delta variant for at least 8 months, studies find

ECMO-free protocol feasible, may aid earlier identification of patients for decannulation

Portable air cleaners could reduce exposure to SARS-CoV-2 aerosols, study finds

References:

Alwakeel AJ, et al. Ann Am Thorac Soc. 2021;doi:10.1513/AnnalsATS.202006-638OC.

Gannon WD, et al. Chest. 2021;doi:10.1016/j.chest.2021.05.066.

Guler SA, et al. Ann Am Thorac Soc. 2021;doi:10.1513/AnnalsATS.202103-266OC.

Lindsley WG, et al. MMWR Morb Mortal Wkly Rep. 2021;doi:10.15585/mmwr.mm7027e1.